Sharper radiation beams aim to improve prostate cancer outcomes
NCT ID NCT07189598
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new type of radiation therapy for men with high-risk prostate cancer that hasn't spread. The treatment uses advanced imaging to deliver higher radiation doses directly to the main tumor while also treating the whole pelvis. Researchers want to see if this approach is more cost-effective and improves survival compared to standard radiation therapy. About 390 men will take part in this Phase III trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adaptive stereotactic body radiotherapy (SBRT) with dose escalation on the dominant prostate tumor
- What this could lead to
- If successful, this approach could offer a more effective and cost-efficient radiotherapy option for high-risk prostate cancer, potentially improving survival and reducing side effects.
- What could go wrong
- This is a Phase III trial, but results are not yet available. The new radiotherapy may not prove better than standard treatment, and there are risks of side effects from higher radiation doses to the prostate and pelvic area.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Eugène Marquis
RECRUITINGRennes, 35000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Man's best friend as cancer detector: can dogs sniff out prostate cancer?
- Can a single radiation type spare prostate cancer patients from extra side effects?
- New scan could reveal hidden cancer in High-Risk prostate patients
- Promising prostate cancer combo trial pulled before starting
- New scan could revolutionize prostate cancer monitoring
- New immunotherapy combo targets High-Risk prostate cancer before and after surgery